Genacol Canada Corporation and Tetra Bio-Pharma Team Up to bring Innovative Cannabinoid Treatments to Self-Care Market in Canada
Momentum Public Relations
Press Release: August 14 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation. Genacol will be responsible for the promotion and sales of these products throughout their network in Canada. According to industry statistics the market for topical pain relief products exceeded $2.5 billion. The companies plan to launch the products in 2019.
|
Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create innovative products for Genacol. Tetra Bio-Pharma will work with regulatory to bring these products to markets within Genacol’s sales network. “We are thrilled to partner with Genacol, a market leader in Canada with a sales network in over 40 countries, these products will command a great deal of exposure,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “Tetra is in the business of developing cannabinoid derived prescription and natural health products and this agreement will enable Tetra Bio-Pharma to expand the number of offerings to our patients.”
“We are extremely excited about the potential of this partnership we have created with Tetra Bio-Pharma, a world leader in developing cannabinoid derived prescription and natural health products,” stated Martin Vidal, President & Chief Executive Office for Genacol Corporation. “Our research team at Genacol are great believers in the therapeutic properties of cannabinoids. These products that Tetra Bio-Pharma is developing and Genacol will promote and commercialize are expected to play an important role in the pain and inflammation market in Canada. We estimate that these products will generate several millions of dollars in sales for Genacol in Canada.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Genacol Corporation
Genacol Corporation Canada is a leader in the development and marketing of natural health products primarily related to the treatment of joint pain and the maintenance of joint health. Its mission is to improve the quality of life of its customers by offering them a range of innovative natural products. Building on its success in Canada, Genacol has also developed in recent years an international presence with Genacol brand products available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. The success of Genacol is based on its collagen manufactured using a proprietary process called “AminoLock® Sequential Technology”, which is an ingredient in many of Genacol’s products.
For more information visit: www.genacol.ca/en/about-us/
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
Media Contact:
ACJ Communication
Daniel Granger
Danel.granger@acjcommunication.com
514-840-7990
514-232-1556
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/b867bc64-b347-4043-80ff-c7d022ab7eff
http://www.globenewswire.com/NewsRoom/AttachmentNg/3464aadf-745d-4d04-b230-b71f0c82188a
- Published in Tetra Bio Pharma
Tetra Natural Health Announces Upcoming Launch of Hemp Energy Drink
Momentum Public Relations
Press Release: July 19 2018
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced that it will be commercializing Hemp Energy Drink, a caffeinated energy drink containing hemp, that received a Temporary Marketing Authorization (TMA) by Health Canada. Tetra intends on launching this product ahead of the upcoming legalization as it begins to position itself as a player in the natural health product market.
Hemp Energy Drink is developed for those who want to have a clear and focused mind and live an active and fun lifestyle. It can be consumed whenever people are in need of energy whilst working, driving or playing sports and leisure activities. The functional benefits of hemp energy drink are mainly to help for concentration, alertness and to contribute to mental performance and reduction of fatigue.
Hemp Energy Drinks are already available in the U.S.A. and in several European countries, and the European Food Safety Authority confirmed the positive health effects related to the ingredients of Hemp Energy Drink.
Tetra Natural Health has a team of natural health experts that have been preparing to commercialize products containing hemp or that act on the cannabinoid receptors under the existing Food and Drug regulations. To lead and support the team, Tetra recently announced the arrival of Richard Giguere, Executive Vice President Commercial Operations who will implement and oversee the natural health product commercial sales and growth strategy.
Richard has more than 20 years’ experience in sales and marketing including OTC, natural products and original pharmaceutical medications. His arrival was perfectly aligned with Tetra Natural Health’s goal to develop and sell hemp, cannabis and cannabinoid-based OTC (self-care) products to leverage the post-legalization market. Tetra obtained the rights to the TMA and plans on expanding this food product line as part of a structured sales driven growth plan.
About Tetra Natural Health:
Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc, (TSX-V: TBP) (OTCQB: TBPMF) that is focusing on retail commercialization of hemp, cannabis or cannabinoid-based products authorized by Health Canada for sale.
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Natural Health Inc.:
Richard Giguere, Executive Vice President, Commercial Operations
richard.giguere@tetrabiopharma.com
438 899-7575 ext 210
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556
- Published in Tetra Bio Pharma
Tetra Bio-Pharma’s Evidence-Based Business Model Confirmed
Momentum Public Relations
Press Release: June 29 2018
Tetra Bio-Pharma Inc.(TBP:V), a leader in cannabinoid-based drug discovery and development, today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model. Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence. As a biopharmaceutical company, Tetra’s orientation is to bring cannabis and cannabinoid-based products to market that meet the regulatory quality, safety and efficacy requirements for prescription medications.
Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids. In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra to collect significant data to support its marketing applications. A similar clinical development program was launched with cannabis oils in preparation for the upcoming post-legalization market. The combination of safety, pharmacokinetic and efficacy data allows Tetra to bring products to market under the proposed new regulatory framework. Tetra Bio-Pharma is one of a few cannabinoid based companies that is committed to providing much needed clinical data for both its pharmaceutical and natural health products.
Over the coming months Tetra Bio-Pharma will deliver its findings in a series of presentations and scientific articles that will be published in 2018 to share the clinical data of both the inhalation and oral clinical development programs with the medical community, beginning with the July 4, 2018 International Cannabinoid Research Society Meeting in the Netherlands where Dr. Maria-Fernanda Arboleda, MD, will present the results of the above clinical trial. http://www.icrs.co/
Update on North Bud Farms Inc.
Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the receipt of North Bud’s preliminary and final prospectus. As one of the closing conditions to the sale these documents must now be submitted by July 31, 2018.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Tetra Bio Pharma
Deloitte Predicts $7 Billion Cannabis Market in 2019
Momentum Public Relations
Blog: June 14 2018
If you thought that all the bargains had already been found in Canada’s nascent marijuana industry, you may just want to think again. The marijuana market still appears to have plenty of legs.
According to a story posted by the CBC on June 5, 2018, accounting firm Deloitte is predicting that Canadians will spend almost $7 Billion on legal and illegal recreational marijuana and on medical cannabis. Deloitte also expects Canadians to increase their marijuana consumption by 35% once the California Rest Cure is legalized.
On June 7, 2018 the Canadian Senate voted on the marijuana bill with numerous amendments. The House of Commons now has the choice of either signing the bill as is or sending it back to the Senate. As slow as the pace is it does appear that marijuana legislation will be passed this year if not this summer.
When that finally happens market watchers expect marijuana stocks to be jolted higher. Marijuana industry valuations have been jumping since the New Year and as far back as January stock market watch dogs have expressed doubts as to the viability of the industry’s bull run.
On January 12, Toronto Star business columnist David Olive wrote that exceptional care needs to be taken in picking marijuana stocks. Among the conditions that have the potential to bring this bull market to its knees Olive included, sky-high stock valuations that have no relationship to earnings: too much competition and the potential of political interference to derail stock prices.
On January 12, Olive noted that there were 259 publicly traded pot stocks in Canada. Olive also noted that when US attorney general commented on his government’s willingness to prosecute marijuana users, Canadian marijuana stocks retreated.
Against this background it is obvious that the market still expects the marijuana industry to become as blue chip as any industry can become in this post-blue chip modern world.
In order to gain economies of scale and secure market share the marijuana industry has been consolidating for some time. In January Edmonton-based Aurora Cannabis bought CanniMed Therapeutics for roughly $1 Billion and in May Aurora bought MedReleaf Corp. for $2.9 Billion.
If you believe that Aurora will be one of the companies dominating its industry then you have the right idea. But it could be much bigger than that. The global recreational and medical marijuana market is in play and Canadian companies stand a good chance in taking the pole position because Canada is the first G7 country to legalize marijuana. Most of the big cannabis companies in Canada have more than one ace up their sleeve and they are investing in the international market.
Aurora, for example, has won the first medical marijuana tender issued by the Italian government. It also has distribution agreements in place with Shoppers Drug Mart and the Societe des Alcools du Quebec, the Quebec provincial liquor monopoly. Canopy Growth, has operations in seven countries on four continents. Aphria Inc. has operations in more than 10 countries on five continents.
If you think the market is now too high to buy in, you may want to think again. A story published in Forbes on March 1, 2018 predicts a robust and growing legal international marijuana poised for exponential growth. Investment bank Bryan, Garnier & Co have just predicted that the global marijuana market is poised to grow by a 1,000 percent to hit US$140 billion by 2027.
At this moment the bull market looks as if it will keep running. Consider this, marijuana companies are still going public. On May 2, 2018 The Green Organic Dutchman Holdings, (TSE: TGOD) listed at $3.61 and sold 31,510,000 shares. TGOD, a licensed producer, has two farms and intends to become the largest organic producer of marijuana in the world, and Canada’s lowest cost producer, specializing in breeding new strains and seeds to meet specific therapeutic targets.
On May 29 FSD Pharma (CSE: HUGE) went public on the Canadian Stock Exchange and broke the record for the largest volume traded in a single first day of trading. As the week went on following its listing on the CSE, things only got better. In the first five consecutive days of its listing FSD Pharma traded exactly 259,230,820 Class B subordinate voting shares, the largest number of shares ever traded by a CSE listed company following listing. With news like this it’s hard to believe that the marijuana market is over.
FSD Pharma, through its wholly owned subsidiary FV Pharma, a licensed producer, intends to build the largest hydroponic cannabis greenhouse in the world in what once was the Kraft production facility in Coburg, Ontario. Currently producing in a 20,000 SF phase one operation the company intends to increase that tenfold by the end of the year.
After that, there’s more room to expand in the 620,000 SF facility that sits on 70 acres of land. FSD Pharma is debt free because of the streaming agreement it made with what now is Auxly, Canada’s first marijuana streaming company, which will finance and advise on operations in return for 49.9% of production in perpetuity.
As the Canadian marijuana industry continues to mature there will be market corrections but on the whole marijuana stocks appear to have very energetic legs.
- Published in Blog
Tetra Bio-Pharma Inc. Provides Corporate Update Ahead of Its Annual General Meeting
Momentum Public Relations
Press Release: June 13 2018
Tetra Bio-Pharma Inc.=(TBP:V) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to provide a Corporate Update on its programs and upcoming milestones in the development of its bio-pharmaceutical and natural health products that address large markets with significant unmet medical needs.
- In Q3 of this year, TBP will file a request to commence a Phase 1 clinical trial for PPP004 our topical product indicated for General Neuropathic Pain, conservatively estimated as a billion-dollar market. Neuropathic pain can be caused by injury or disease and can be associated with such common conditions as shingles, diabetic neuropathy, multiple sclerosis, spinal stenosis and sciatica among other conditions.
- In Q3, we anticipate filing a request to commence a Phase 1 clinical trial for PPP003 an ocular treatment for eye pain and inflammation and dry eye. The company has identified one lead compound that is a non-scheduled 1 cannabinoid which would significantly reduce time to market as is it not considered a controlled substance. TBP is also exploring conducting a study focused on Dry-Eye, in the USA.
- Tetra-Bio-Pharma anticipates launching its Rx Oil capsules for the treatment of chronic pain and cancer pain in Q3 of this year. The company is presently conducting a Phase IV study expected to be completed in Q3 and we expect the launch to occur in Q3.
- We expect to complete our Phase III trial for PPP001 in Q4/2018, Q1/2019 and will file for approval in Q1 of 2019. Tetra will seek additional indications for this product and we will announce our intentions soon.
- In Q3, we expect to launch our bioavailability study for PPP0002, and if we prove equivalence to the referenced product, Tetra anticipates filing for approval under the 505 (B) 2 route in the USA in Q4 2018. In addition, Tetra expects to commence a Phase II study in chronic pain with PPP002 in Q3 of this year.
- Legalization of recreational cannabis is expected to take place in Q3/Q4 of this year following which Tetra Bio-Pharma will launch no fewer than 7 cannabinoid based Natural Health products in the Canadian market. We will also look to license these products worldwide.
“Tetra Bio-Pharma has come a long way in the last 12 months and the momentum is building as we advance our products through various phases of clinical development, thereby answering the need for rigorous scientific evidence. We believe our independently credentialed clinical development work, in combination with the launch of our natural health products will be instrumental in building shareholder value,” stated Guy Chamberland Interim CEO and CSO for Tetra Bio-Pharma.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant-based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Executive Vice President, Corporate Development & Licensing
(514) 817-2514
For investors information, please contact:
investors@tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Tetra Bio Pharma
Tetra Bio-Pharma Inc. Strengthens Senior Management Team
Momentum Public Relations
Press Release: June 5 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX-V:TBP) (OTCQB:TBPMF), has strengthened its management team with the promotion of V.P. Financing and Business Development Robert (Bob) Bechard to Executive Vice President, Corporate Development and Licensing, and the hiring of Ofer Yifrach-Stav as Vice President Pharmaceutical Compliance and Quality.
In his new expanded role, Bob will lead Tetra Bio-Pharma’s business development and be actively involved in fundraising and executing the Company’s M&A strategy, while overseeing Investor Relations.
Bob has more than 25 years’ experience in financing, including venture capital and corporate banking along with business development. He was a Senior Member of a Venture Capital fund that delivered top quartile returns investing in North American Biotech companies. During his venture days, he served on the Boards of more than 30 biotech companies and oversaw the negotiation of numerous strategic alliances with major pharmaceutical companies. Additionally, he managed numerous exits via the public market or an outright sale to large pharmaceutical companies on behalf of the venture capital funds. Bob brings sound operational experience from his time as Chief Business Officer for an R&D Management company and VP of Corporate Development for a drug delivery company. As a consultant, he assisted numerous biotech companies in the areas of fundraising, business development, corporate development and strategy.
“We are thrilled to have Bob as an integral member of Tetra Bio-Pharma’s Senior Executive team. His vast experience and extensive international network will help drive the execution of our corporate strategy,” said Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.
“I am excited to be able to play a more active role in helping Tetra Bio-Pharma realize its vision to make pharmaceutical grade cannabinoid-based products accessible to patients around the world,” said Bob Bechard, EVP, Corporate Development and Licensing.
The new Vice President Pharmaceutical Compliance and Quality, Ofer Yifrach-Stav has extensive experience in pharmaceutical and medical device industries where he worked with major medical device, pharmaceutical and cosmetic companies in North America, Europe and Asia. During this time, he successfully lead the preparation of companies for Quality Audits by Health Canada, FDA, EU and Israeli Ministry of Health. Over the years he developed expertise in production process validations and other areas of quality assurance.
“Ofer Yifrach-Stav will play a key role in accelerating our pre-commercial activities in preparation of the marketing applications of PPP001 and PPP002. These activities include production scale-up activities and process validations required to ensure the completeness of the Quality file required for the marketing applications leading to the DIN,” added Guy Chamberland.
The corporation will be restructured to optimize operations by commercial markets. Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization. Tetra Veterinary Health was created for the commercialization of cannabinoid-based products for the pet product market. To take advantage of the post-legalization market, Tetra Natural Health was established to develop and sell cannabinoid-based OTC (self-care) products.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its vision, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Tetra Bio Pharma
Relevium Selects 93,000 Sq. Ft Organic Cultivation Facility in Quebec
Momentum Public Relations
Press Release: June 4 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that, through its wholly-owned subsidiary Biocannabix (“BCX”), it has selected a 93,000 square foot facility in Montreal, Quebec with the objective of cultivating premium organic cannabis.
With the assistance of PipeDreemz Inc., Relevium has conducted initial assessment on the facility, a 93,000 Sq. Ft industrial building located adjacent to the TransCanada Highway, Trudeau International Airport and about 20 minutes from downtown Montreal. The building has been selected as a desirable location with a low risk profile for the application submission to Health Canada for an ACMPR cultivation license. Biocannabix will be leveraging the vast experience of lead consultant George Routhier and his company PipeDreemz Inc., a company with a remarkable 100% rate of success with ACMPR licensing from Health Canada.
Company Strategy
The strategy for the Company is to cultivate high quality organic strains for use in exclusive, high-end consumer packaged goods primarily for health and wellness. The Company will not compete on large scale supply, but rather plans to focus on custom niche and organic products with established partnerships for processing and ongoing research in cannabis derivatives.
The Company intends to develop the project in stages and expects to retrofit the building with an initial phase of 10,000 Sq. Ft of cultivation. Upon the completion of the first stage, successful operations and licensing, the company will then proceed with phases 2 and 3. Construction of the project is subject to financing and customary approvals.
Aurelio Useche, CEO of Relevium stated: “The strategy of Biocannabix will not be catered around being the lowest cost producer, but rather on being a premium and custom producer focused on consumer packaged goods to be sold through Relevium’s current and new brands.” Mr. Useche stated further: “The value in the supply chain will be in developing trusted, unique, ultra-premium product for luxurious brands.”
About PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Marijuana Stocks Still Have Legs
Momentum Public Relations
Blog: June 1 2018
Marijuana Stocks Still Have Legs
Bryan, Garnier & Co: Global Marijuana Market to Hit US$140 Billion by 2027
Canadian Licensed Producers Expanding Abroad
The exact date when recreational marijuana will be legalized is still uncertain. The Trudeau government has repeatedly said that it will be legalized this summer. When that great day comes to pass it may be the only time in Canadian history that the government has created an economic stimulus package that actually works: the legal marijuana industry.
Not content with only being valued in the billions of dollars in Canada, our domestic marijuana industry is also hell-bent on international expansion.
On January 28, 2018 the CBC ran a story quoting Bloomberg that said there were 87 publicly listed marijuana companies on the TSXV and that collectively they were worth US$37 billion. In January Statistics Canada estimated that almost 5 million Canadians spent $5.7 billion dollars buying marijuana, with only 10% of that going to legal medical cannabis.
On May 28, 2018 Aurora Cannabis announced that it had signed a distribution agreement with German plant based pharmaceutical distributor Heinrich Klenk. Klenk distributes its products in more than 25,000 drug stores across Germany and Europe. Klenk is a trusted name and Aurora has launched a new brand that will be produced in Canada named Cannabis Klenk which the company will distribute. Medical cannabis is legal in Germany.
Aurora has been making international plans and putting them into action for some time. It owns Berlin-based Pedanios, the leading marijuana importer, exporter and distributor of medical marijuana in the European Union as well as 51% of Aurora Nordic which plans on constructing a one million square foot greenhouse in Denmark. To round out its diversified activities the company also owns two companies that specialize in building greenhouse lighting systems, BC Northern Lights and Urban Cultivator.
Aurora is not alone on the international stage, Canopy Growth, which has Snoop Dogg as a spokesman, has operations in seven countries on four continents. Aphria Inc. has operations in more than 10 countries on five continents. It recently created a joint venture, Canninvest Africa with the South African Verve Group of Companies that will see it gain an interest in Verve Dynamics, a licensed producer of medical cannabis extracts, which it believes will become one of if not the lowest cost producer in the extract field.
Driven by economies of scale and the desire to have all the pieces to the puzzle in one place the industry has been consolidating for some time. The most recent example is the merger of Aurora and MedReleaf, which has created the largest marijuana company in the world.
If you think the market is now too high to buy in, you may want to think again. A story published in Forbes on March 1, 2018 predicts a robust and growing legal international marijuana poised for exponential growth.
The story is based on a report by Arcview Market Research which predicts that by 2027 spending on legal recreational and medical marijuana will hit US$57 billion with a 67% market share for recreational marijuana and a 33% share for medical cannabis.
The lion’s share of the revenues will be generated in North America where the largest recreational market is expected to develop with sales going from US$9.2 billion in 2017 to US$47 billion in 2027.
All of which means that serious investors should start doing their due diligence on the marijuana industry now, if they haven’t already. That due diligence should also include bio-pharmas that are developing cannabis- based drugs for regulatory approval and for the over the counter market.
If you still think that marijuana stocks are overpriced you may wish to consider this, investment bank Bryan, Garnier & Co have just predicted that the global marijuana market is poised to grow by a 1,000 percent to hit US$140 billion by 2027.
One of the more interesting set of statistics put out by Statista is that in America, medical marijuana will take a larger slice of the pie than recreational marijuana. The company predicts that by 2025 cannabinoid-based pharmaceuticals will be valued at US$13.2 billion and the legal recreational market at US$10.9 billion.
Whether or not cannabinoid-based pharmaceuticals will surpass the legal recreational market is as yet unknown but predictions like the one above are a sure indication that bio-pharmas launching successful drugs will be lucrative.
A rising tide raises all ships. When Canadian recreational marijuana legalization takes place marijuana stocks are expected to jump and by association so will those pharmaceutical companies developing successful cannabinoid-based drugs.
Tetra Bio-Pharma, (TSXV: TBP) is one such company with a pipeline of cancer chronic pain, and other products under development. Its lead product, PPP 001, trademarked as RX Princeps has started Phase 3 clinical trials and stands to be the first cannabinoid therapy that will have its efficacy and safety proved.
Once that happens, PPP 001 will very likely become the first drug to be given Health Canada and American FDA approval. This achievement will be marked by a Drug Identification Number, DIN, which means that it can legally be prescribed by doctors and eligible for insurance plan coverage. TBP already has distribution agreements in place in Israel and in Europe.
The above does not and should not be taken as investment advice. Investors have the responsibility of performing their own due diligence. In the interests of transparency, Momentum PR represents Tetra Bio-Pharma.
- Published in Blog
Relevium Engages PipeDreemz as Lead ACMPR Consultant for Biocannabix
Momentum Public Relations
Press Release: May 17 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has engaged PipeDreemz as lead consultant (the “Consultant”) for the Biocannabix Health Corp (“BHC”) ACMPR applications to Health Canada to obtain the necessary licenses. Biocannabix will focus on organic products and on the development of specialty genetic strains targeting primarily cannabidiol (CBD) and cannabigerol (CBG) for use in medical applications as well as consumer packaged goods.
Highlights
- Industry veteran Georges Routhier and PipeDreemz have been providing advisory services to a number of successful Licensees
- Instrumental in designing the H2 Biopharma facility in Lachute, Qc., acquired by Aurora Cannabis
- The PipeDreemz team holds advanced degrees in science, engineering, business, agriculture, horticulture and plant sciences
- As at January 1, 2018 PipeDreemz had 23 highly advanced facilities under construction across Canada
- ACMPR license application submission forecasted for Summer 2018
Aurelio Useche, CEO of Relevium stated: “Since the creation of Biocannabix Health Corp, a wholly-owned subsidiary of Relevium, we have interviewed a multitude of cannabis consultants, key industry suppliers and advisors with a focus on the Quebec market.” Mr. Useche continued: “We are extremely pleased to partner with George Routhier and the team at PipeDreemz who were highly recommended by industry insiders. George is a veteran in the industry, has a proven track record and shared values with Relevium in terms of the evolution of the cannabis business both in Canada and around the world.”
The Company will begin working immediately with the PipeDreemz and its advisors in the evaluation of selected locations in and around Montreal, Quebec, where the company will host its operations. All facets of the operations, from HVAC to security, genetics and micropropagation, to distribution and branding will be taken into consideration in order to ensure aligned strategic fit and the best possible long-term ROI for the company and its shareholders.
The Company anticipates that the application will be deposited to Health Canada before July 31, 2018.
More about PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
PipeDreemz cemented its position as an expert in the cannabis field following the sale of a PipeDreemz designed state-of-the-art, 49,000 square foot cannabis production facility to Aurora Cannabis Inc. H2 Biopharma retained PipeDreemz for start to finish services including design and oversight on construction of the facility, located in Lachute, Quebec. Aurora Cannabis Inc. acquired the PipeDreemz designed facility from H2 Biopharma in November 2017.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Creates Cannabis Brands for North-American Market
Momentum Public Relations
Press Release: April 26
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of its two first cannabis brands, LeefyLyfe and Biocannabix offering cannabis products in the North-American and European markets. LeefyLyfe and Biocannabix brands are part of the wholly owned Biocannabix Health Corporation (the “Subsidiary” or “BHC”).
Highlights
- Biocannabix® will target the Canadian market pursuant to ACMPR regulations
- LeefyLyfe® will target CBD sales outside of Canada in full compliance with local legal and regulatory framework
- All resources being pooled to fast track the company’s positioning in the cannabis space
Aurelio Useche, CEO of Relevium stated: “We believe the organizations that build credible, trusted and recognizable brands in the CBD market will be the winners in this already fragmented space. At RLV, we are leveraging our current branding and online abilities in combination with all the resources at our disposal internally and externally to position the Company in the consumer products cannabis space.” Mr. Useche continued: “From formulation to branding and e-retail, we will be able to monetize CBD and CBG based consumer products outside of the Canadian market while the application for an ACMPR license for Canada is being worked on. We believe that this approach provides the best balance of short and mid-term ROI and an ideal risk ratio.”
Biocannabix
Relevium will be building the Biocannabix® brand in for the Canadian market and focus the brand architecture towards the medical and health markets. The Company has secured http://biocannabix.com/as the domain for the brand.
In order to gain access to the cannabis for medical purposes market and obtain the necessary licenses from Health Canada, including the ACMPR license, the Company has begun the process of evaluating locations in Quebec that could accommodate the operation. The Company has studied industry peers and believes that with the amount of data available it will be able to act swiftly and in a very cost-effective manner.
LeefyLyfe
Relevium will be building LeefyLyfe® as an elevated and trusted brand for the health-conscious consumer outside of Canada, with a focus on full spectrum hemp, CBD and CBG formulations aimed for lifestyle, health and wellness. The product offering targetsapplications ranging from pain relief and anti-inflammation to anxiety and sports performance. The Company has secured http://leefylyfe.com/ as the domain for the brand.
Relevium has already shortlisted production partners that would be able to meet stringent legal and compliance guidelines. All products being contemplated for the LeefyLyfe® brand will be derived from American grown, organic and non-genetically modified hemp.
The Company projects sales for LeefyLyfe® to commence in Summer in full compliance with rules, regulations and laws at the State and Federal levels.
Building a Brand Portfolio
In full alignment with the company’s business strategy, management is engaged in a process to secure branding licensing agreements and endorsement opportunities tailored for different consumer segments in this market. As opportunities arise, they will be subject to focus group and SWOT analysis in order to evaluate a proper risk/reward for the Company. The Company anticipates having a high-end premium or luxury brand offering in the spring or summer depending on a variety of factors.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies